Cell and advanced therapies supply chain management market

1. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions Roots Analysis https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.html https://www.rootsanalysis.com/ https://www.rootsanalysis.com/reports/

2. Overview Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions. In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma® (2019), RECELL® System (2018), AmnioFix® (2018), EpiFix® (2018), EpiBurn® (2018), Alofisel® (2018), LUXTURNA™ (2017), Yescarta® (2017), and Kymriah® (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies. In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

4. Scope of the Report The ‘Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030’ report features an extensive study of the growing supply chain management software solutions market. The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies. Amongst other elements, the report features: A detailed assessment of the current market landscape, featuring a comprehensive list of over 160 technological platforms that are being used to manage the cell and advanced therapies supply chain, along with information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others). An insightful company competitiveness analysis, taking into consideration the supplier power (based on their employee base and years of experience in the industry) and portfolio-related parameters, such as number of software solutions offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits. ■ ■

6. An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are engaged in this field. An analysis of the partnerships that have been established in the domain, in the period between 2014 and Q3 2019, covering software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and other relevant deals. A detailed analysis of the platform utilization use cases where aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019, highlighting the ways in which companies have implemented such systems to improve / optimize various supply chain-related processes of cell and advanced therapies. An in-depth analysis of the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems. A case study on COPs, featuring insights on their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the cell and advanced therapies supply chain. In addition, it provides a brief discussion on the growing popularity of COPs on the social media platform, Twitter. ■ ■ ■ ■ ■

8. The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific) Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult) Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) and Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson) Martin Lamb (Chief Business Officer, TrakCel) ■ ■ ■ ■ All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

10. Contents Chapter Outlines Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the cell and advanced therapies supply chain solutions market in the mid to long term. Chapter 3 is an introductory chapter that presents a general overview of the cell and advanced therapies domain, along with details on the various types of such products and the current therapy landscape. It features a detailed discussion on the cell and advanced therapies supply chain and key challenges related to different processes / stakeholders involved in this segment of the industry. The chapter also provides information on various software-enabled systems, highlighting their key advantages and associated challenges. Further, the chapter describes the key growth drivers and roadblocks related to the use of such solutions in the cell and advanced therapies supply chain, offering insights on the emergence of advanced, digital technologies in the domain, as well.

11. Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com https://www.rootsanalysis.com/reports https://www.rootsanalysis.com/press-releases.html Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research